Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R)

Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R)
(insulin degludec/insulin aspart) receive positive opinions from the
European regulatory authorities 
BAGSVAERD, DENMARK -- (Marketwire) -- 10/19/12 --  
Company Announcement No 66 / 2012:
http://hugin.info/2013/R/1650358/532183.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 


 
(i)  the releases contained herein are protected by copyright and
     other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

 
Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1650358] 
Further information: 
Media:
Mike Rulis
Tel: (+45) 3079 3573
mike@novonordisk.com 
Investors: 
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com 
In North America: 
Ambre Morley
Tel: (+1) 609 216 5240
abmo@novonordisk.com 
Jannick Lindegaard
Tel: (+1) 609 786 4575
jlis@novonordisk.com
 
 
Press spacebar to pause and continue. Press esc to stop.